News

AmMax to participate in Cowen Conference on March 3rd. Read More>

AmMax Bio, Inc.

Slogan 2020 AmMax white 3 lines.png
shutterstock_1174276207_edited_edited.jp
 
shutterstock_724957504_edited.jpg

ABOUT US​

Launched in March 2020 out of a partnership between LifeMax and Amgen, AmMax Bio, Inc. (“AmMax”) is a privately held, clinical stage biotech company focused on unlocking the therapeutic potential of the CSF1R platform (“colony stimulating factor 1 receptor”) to address diseases with significant unmet medical needs and sizable market potential. We have two clinical stage programs ready to enter Phase 2 studies.

April 29, 2021
AmMax Bio to Present at the BofA Securities 2021 Virtual Healthcare...

REDWOOD CITY, Calif. Apr. 29, 2021 — AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X ...

March 2, 2021
AmMax Bio Announces the Appointment of Biotechnology Executive ...

REDWOOD CITY, Calif. March 2, 2021 — AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative treatments with its proprietary dual anti ...

February 16, 2021
AmMax Bio to Participate in the 41st Annual Cowen Health Care ...

REDWOOD CITY, Calif. February 16, 2021 — AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company focused on developing first-in-class or best-in-class treatments ...

NEWS

shutterstock_1682600770_edited.jpg

R&D

AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis and polycystic kidney diseases, by leveraging the action of AMB-05X on inflammation, fibrosis and neovascularization.

News

AmMax Bio to Present

at BofA Investor Conference...

Read More>